Summary & Overview
HCPCS J9382: Injection, zenocutuzumab-zbco, 1 mg
HCPCS Level II code J9382 designates a billing unit for zenocutuzumab-zbco, an injectable monoclonal antibody dosed per milligram. As a drug-specific HCPCS code, J9382 matters nationally because it standardizes reporting and reimbursement for a targeted oncology therapy across outpatient infusion centers, specialty clinics, and hospital outpatient departments. Clear coding for high-cost biologics supports accurate claims processing, utilization monitoring, and payment policy development.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code represents, payer coverage considerations, common billing modifiers, and the typical care settings where the product is administered. The publication outlines benchmarks for unit reporting, notes typical sites of service for injectable oncology agents, and identifies gaps where payer-specific coverage details and ICD-10 linkage are not available in the input.
This summary equips coding professionals, billing managers, and policy analysts with a concise reference to the clinical and billing context of HCPCS Level II code J9382, supporting consistent claim submission and administrative planning for outpatient antineoplastic therapies.
Billing Code Overview
HCPCS Level II code J9382 — Injection, zenocutuzumab-zbco, 1 mg — represents a billed drug administration unit for the monoclonal antibody agent zenocutuzumab-zbco. The service type is drug administration for an oncologic biologic agent provided as an injectable medication. The typical site of service is outpatient infusion or oncology clinic settings where parenteral antineoplastic or targeted therapies are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with advanced, refractory, or metastatic solid tumor harboring an NRG1 gene fusion or other actionable HER-family pathway alteration for which zenocutuzumab-zbco is indicated. The patient has prior lines of systemic therapy and is referred to an oncology infusion center for targeted monoclonal antibody therapy. Prior to treatment, the oncology team reviews molecular testing results, verifies insurance authorization, confirms baseline labs (CBC, CMP), and documents performance status and infusion consent. On the day of service the patient is assessed for vital signs and infusion reaction risk; antiemetics or premedications are administered per protocol. The medication J9382 is prepared by pharmacy in a sterile compounding area, labeled by milligram dose, and delivered to the infusion nurse. The drug is administered intravenously over the protocol-specified infusion time with continuous monitoring for infusion-related reactions. Post-infusion observation is performed per protocol and any adverse events are documented in the medical record. Billing uses the HCPCS Level II code J9382 reported per milligram. Applicable modifiers (for example JW for discarded drug or QX for modifier indicating CLIA-waived practitioner) are appended as clinically appropriate during claim submission. Typical site of service is an outpatient hospital infusion center or freestanding oncology infusion clinic. Typical patient scenario: adult with metastatic carcinoma and documented NRG1 fusion receiving treatment as a second- or later-line targeted therapy in a monitored infusion center after molecular testing confirmation and payer authorization.
Coding Specifications
| Modifier |
|---|